Skip to main content

Table 1 Baseline clinical characteristics of patients with and without RVSD

From: Right ventricular systolic dysfunction and remodelling in Nigerians with peripartum cardiomyopathy: a longitudinal study

Variables Patients with RVSD N = 32 (71.1 %) Patients without RVSD N = 13 (28.9 %) p-value
Age (years) 26.1 ± 7.5 27.7 ± 5.4 0.500
NYHA class:    0.809
 II 13 (40.6 %) 6 (46.2 %)  
 III 12 (37.5 %) 5 (38.5 %)  
 IV 7 (21.9 %) 1 (7.7 %)  
 Parity ≥2 25 (78.9 %) 10 (76.9 %) 0.758
 Breastfeeding 30 (93.8 %) 13 (100 %)
 BMI (Kg/m2) 21.4 ± 4.6 21.9 ± 3.9 0.704
 Systolic BP (mmHg) 116 ± 23 128 ± 26 0.172
 Diastolic BP (mmHg) 83 ± 18 94 ± 16 0.051
 Heart rate/min 111 ± 16 104 ± 21 0.302
 Pedal oedema 26 (81.3 %) 8 (61.5 %) 0.312
 Hepatomegaly 19 (59.4 %) 6 (46.2 %) 0.515
 Pregnancy associated hypertension 13 (40.6 %) 9 (69.2 %) 0.158
 Haemoglobin (g/dL) 12.2 ± 1.8 12.9 ± 1.3 0.202
 Log10 Creatinine 2.0 ± 0.2 1.9 ± 0.1 0.020*
 Sodium (mmol/L) 136.3 ± 6.3 135.5 ± 5.2 0.655
Treatment:
 ACEI/ARB 15 (46.9 %) 7 (53.9 %) 0.749
 Frusemide 32 (100 %) 13 (100 %)
 Spironolactone 31 (96.9 %) 11 (84.6 %) 0.196
 Digoxin 28 (87.57 %) 12 (92.3 %) >0.999
 Beta blockers 2 (6.3 %) 1 (7.7 %) >0.999
 Warfarin 1 (3.1 %) 1 (7.7 %) 0.499
 α-Methyl Dopa 4 (12.5 %) 2 (15.4 %) >0.999
  1. Key: NYHA New York Heart Association functional classification, BMI body mass index, ACEI angiotensin concerting enzyme inhibitors, ARB angiotensin receptor blockers. Results are presented as means ± standard deviations, or as numbers with percentages in parentheses. * p-vlaue is statistically significant